Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Published byGülistan Kızılırmak Modified over 5 years ago

Similar presentations

Presentation on theme: "Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)"— Presentation transcript:

1 Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN) sites  M. Stasenko, R.K. Reynolds, M. Brackmann, K. McLean, R. Spencer, S. Uppal, C.M. Johnston  Gynecologic Oncology  Volume 141, Pages (June 2016) DOI: /j.ygyno Copyright © Terms and Conditions

2 Fig. 1 NCCN Sites Adherence to Hematologic Hold Parameters.
Gynecologic Oncology  , DOI: ( /j.ygyno ) Copyright © Terms and Conditions

Download ppt "Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)"

Similar presentations

Port site metastasis after robotic-assisted laparoscopic hysterectomy for uterine cervical cancer: A case report and literature review BoKyong Kim, Seung.

Port site metastasis after robotic-assisted laparoscopic hysterectomy for uterine cervical cancer: A case report and literature review BoKyong Kim, Seung.
Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /

Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /
Nicoletta Colombo, Martin Gore 

Nicoletta Colombo, Martin Gore 
Volume 144, Issue 1, Pages (January 2017)

Volume 144, Issue 1, Pages (January 2017)
The case for wider use of recombinant factor VIII concentrates

The case for wider use of recombinant factor VIII concentrates
Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey  Lazzaro Repetto  Critical.

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey  Lazzaro Repetto  Critical.
Volume 64, Pages e1-e3 (January 2017)

Volume 64, Pages e1-e3 (January 2017)
Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward 

Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward 
Critical Reviews in Oncology / Hematology

Critical Reviews in Oncology / Hematology
Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
Are patients willing to travel for better ovarian cancer care?

Are patients willing to travel for better ovarian cancer care?
L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L
Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)
Volume 146, Issue 3, Pages (September 2017)

Volume 146, Issue 3, Pages (September 2017)
A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L
Volume 145, Issue 2, Pages (May 2017)

Volume 145, Issue 2, Pages (May 2017)
Vulvar intraepithelial neoplasia: Risk factors for recurrence

Vulvar intraepithelial neoplasia: Risk factors for recurrence
Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008]  Douglas.

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008]  Douglas.

Similar presentations

Ads by Google